ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年01月20日 14時00分
Source:
Eisai
エーザイ、CDP気候変動レポート2019において最高評価であるAリストに選定
東京, 2020年01月20日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、非営利団体である CDPが発行した気候変動レポート 2019 において、気候変動対応で特に優れた活動を行っている企業として最高評価の A リストに選定されましたのでお知らせします。
CDP はロンドンに拠点を置く非営利団体であり、主要国の時価総額上位企業や自治体に対し気候変動・水・森林に関する情報開示を求め、分析・評価した上で、投資家、企業および政府に開示しています。
当社は、「エーザイ・ネットワーク(ENW)企業環境方針」に基づき、全社員が環境保全の重要性を認識し、地球環境との調和をめざした事業活動を展開しています。特に気候変動については、社会が直面する重要課題として位置づけ、2019 年に Science Based Targets(SBT)イニシアチブから認定された科学的根拠に基づく温室効果ガス排出削減目標を定め、取り組みを強化しています。また、気候関連財務情報開示タスクフォース(TCFD)のフレームワークを活用し、気候変動が当社の事業活動に与える影響を中長期的に捉え、ビジネス上のリスク低減と機会創出に取り組んでいます。
当社は、患者様とそのご家族の喜怒哀楽を第一義に考え、そのベネフィット向上に貢献し、世界のヘルスケアの多様なニーズを充足することを企業理念と定めています。このヒューマン・ヘルスケア(hhc)理念のもと、気候変動に対する取り組みを強化し、社会の持続性確保に貢献してまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202003.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Approval in Principle (AiP) for the Basic Design of a Large Ammonia-Fueled Ammonia Carrier Obtained from Classification Society
Mar 14, 2025 18:37 JST
Toyota Launches All-New Crown Estate in Japan
Mar 14, 2025 17:22 JST
Hokkaido Electric Power Corporation and Mitsubishi Corporation Establish a Joint Venture "Hokkaido Renewable Energy Aggregation Co., Ltd."
Mar 13, 2025 13:26 JST
Lexus Presents the World Premiere of the New "RZ"
Mar 12, 2025 17:45 JST
MHIET Achieves Rated Operation of a 6-Cylinder 500kW-class Hydrogen Engine Generator Set
Mar 12, 2025 14:11 JST
MOL and Fujitsu leverage AI for efficient crew replacement planning
Mar 12, 2025 13:53 JST
JCB Now Available on Google Play in Thailand, Indonesia, Vietnam, Philippines, and Hong Kong
Mar 12, 2025 11:00 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Develops Miniaturized Micro Profile, a Next-Generation Contact tape for Fifth-Generation Signal Relays
Mar 12, 2025 11:00 JST
JCB Announced Premier Sponsorship for the 10th Edition of Sakura 2025 at Singapore's Gardens by the Bay
Mar 11, 2025 18:00 JST
Hitachi Energy invests additional $250 million USD to address global transformer shortage
Mar 11, 2025 17:49 JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 10, 2025 20:24 JST
CEPI funds Nagasaki University to develop innovative vaccines using Nanoball platform and NEC's AI
Mar 10, 2025 12:10 JST
Japan's Telecommunications Carriers Enhance Disaster Response with On-site Training for Joint Use of Marine Vessels
Mar 07, 2025 16:24 JST
NEC improves the energy efficiency and floor space density of 5G Mobile Core systems
Mar 06, 2025 13:20 JST
Unmanned Aerial Vehicles Being Developed by MHI Used in Demonstration of Automated Transport and Unloading of Heavy Cargo in Disaster Areas
Mar 05, 2025 16:11 JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 05, 2025 09:09 JST
MHI-MS Completes Domestic Development of Vehicle Transport Robot
Mar 04, 2025 19:39 JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 04, 2025 17:22 JST
Prideone Entertainment announces concept for post-war film to mark 80th anniversary of the end of World War II
Mar 04, 2025 16:00 JST
NTT and DOCOMO Successfully Demonstrates On-Demand Unified Control of Computing Services Through Network and Service Integration
Mar 03, 2025 20:25 JST
More Latest Release >>
Related Release
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
3/3/2025 1:53:00 PM JST
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
2/28/2025 12:31:00 PM JST
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2025 1:29:00 PM JST
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
2/14/2025 12:09:00 PM JST
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
2/3/2025 5:23:00 PM JST
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/28/2025 9:46:00 AM JST
More Press release >>